It is made available under a CC-BY-NC-ND 4.0 International license .

1 Smoking, all-cause, and cause-specific mortality in individuals with diabetes

2 in Mexico: an analysis of the Mexico City Prospective Study

Daniel Ramírez-García^{1,2}, Carlos A. Fermín-Martínez^{1,3}, Paulina Sánchez-Castro^{1,2},
Alejandra Núñez-Luna^{1,2}, Martín Roberto Basile-Alvarez^{1,2}, Luisa Fernández-Chirino¹,
Arsenio Vargas-Vázquez², Juan Pablo Díaz-Sánchez³, Ashuin Kammar-García¹, Paloma
Almeda-Valdés⁵, Jaime Berumen-Campos⁶, Pablo Kuri-Morales^{4,7}, Roberto Tapia-Conyer⁴,
Jesus Alegre-Díaz⁶+, Jacqueline A. Seiglie^{8,9}+, Neftali Eduardo Antonio-Villa¹⁰+, Omar
Yaxmehen Bello-Chavolla^{1,7}+*

9

10 +Joint Last authorship

11

12 ¹Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico. ²Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. ³MD/PhD 13 14 (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico. ⁴Especialidad en Medicina Preventiva, Instituto Nacional de Salud 15 16 Pública, Mexico City, Mexico. ⁵Department of Endocrinology and Metabolism, Instituto 17 Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ⁶Experimental Research Unit, Faculty of Medicine, National Autonomous University of 18 Mexico, Mexico City, Mexico. ⁷Instituto Tecnológico y de Estudios Superiores de 19 20 Monterrey, Monterrey, Mexico. ⁸Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. ⁹Department of Medicine, Harvard Medical 21 School, Boston, Massachusetts, USA. ¹⁰Department of Endocrinology, Instituto Nacional 22 23 de Cardiología Ignacio Chávez, Mexico City, Mexico.

It is made available under a CC-BY-NC-ND 4.0 International license .

25 Correspondence:

- 26 Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional de Geriatría.
- 27 Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City,
- 28 Mexico. Phone: +52 (55) 5548486885. E-mail: oyaxbell@yahoo.com.mx
- 29 **Funding:** This research was supported by Instituto Nacional de Geriatría in Mexico.
- 30
- 31 **CONFLICT OF INTERESTS:** The authors declare that they have no conflict of interests.
- 32
- 33 **3,158 text words; 33 references; 3 figures, 2 tables.**
- 34 **Running headline:** Smoking and mortality in diabetes in Mexico

It is made available under a CC-BY-NC-ND 4.0 International license .

36 ABSTRACT (268 WORDS)

BACKGROUND: Evidence from low- and middle-income countries regarding the effect of
smoking in people with diabetes is lacking. Here, we report the association of smoking with
mortality in a large cohort of Mexican adults with diabetes.

METHODS: Participants with diabetes mellitus (self-reported medical diagnosis, use of
 antidiabetic medications or HbA1c ≥6.5%) aged 35-74 years when recruited into the
 Mexico City Prospective Study were included. Cox regression confounder-adjusted
 mortality rate ratios (RRs) associated with baseline smoking status were estimated.

44 FINDINGS: Among 15,975 women and 8225 men aged 35-74 years with diabetes but no 45 other comorbidities at recruitment, 2498 (16%) women and 2875 (35%) men reported 46 former smoking and 2753 (17%) women, and 3796 (46%) men reported current smoking. 47 Smoking less than daily was common: 39.4% of female current smokers and 30.7% of 48 male current smokers. During a median of 17 years of follow-up there were 5087 deaths at 49 ages 35-74 years. Compared with never smoking, the all-cause mortality RR was 1.08 (95%CI 1.01-1.17) for former smoking, 1.09 (95%CI 0.99-1.20) for non-daily smoking, 50 51 1.06 (95%CI 0.96-1.16) for smoking <10 cigarettes per day (median during follow-up 4 cigarettes/day) and 1.28 (95% CI 1.14–1.43) for smoking ≥10 cigarettes/day (median 52 53 during follow-up 15 cigarettes/day). Excess mortality among current daily smokers was greatest for COPD, lung cancer, cardiovascular diseases, and acute diabetic 54 55 complications.

56 INTERPRETATION: In this cohort of Mexican adults with diabetes, low-intensity daily 57 smoking was associated with increased mortality, despite observing smoking patterns 58 which are different from other populations. Of those smoking ≥10 cigarettes per day, over 59 one fifth were killed by their habit. Quitting substantially reduced these risks.

60 **Keywords:** Smoking, diabetes, mortality, Mexican population

It is made available under a CC-BY-NC-ND 4.0 International license .

61 **RESEARCH IN CONTEXT**

62 Evidence before this study

63 We conducted a search in PubMed to identify studies on smoking-related mortality in individuals with diabetes before September 1st, 2023, using the terms ((diabetes mellitus) 64 65 OR (type 2 diabetes mellitus)) AND ((smoking) OR (tobacco)) AND ((mortality) OR (survival analysis) OR (death)). We identified a meta-analysis published in 2015 which 66 67 analysed data from 1,132,700 participants with diabetes from 89 cohort studies. Among 68 current and former smokers, the pooled adjusted relative risk for all-cause mortality was 69 1.55 (95% CI 1.46-1.64) and 1.19 (95% CI 1.11-1.28), respectively. Among current 70 smokers, there was considerably higher risk of death due to cardiovascular disease, 71 coronary heart disease, stroke, peripheral arterial disease, and heart failure. Most included 72 studies were conducted in high income countries and only one was done in Latin America 73 (Argentina, 1,730 participants). In Mexico, epidemiological studies related to smoking have 74 been primarily descriptive in nature. A previous study of the MCPS that analysed all-cause 75 smoking-related mortality among disease-free individuals found adjusted rate ratios among 76 daily smokers of 1.17 (95% CI 1.10-1.25) for those using <10 cigarettes/day and 1.54 77 (95% CI 1.42–1.67) for those using ≥10 cigarettes/day. In this study, mortality risk in 78 people with diabetes was not assessed separately. Instead, mortality risk estimates were 79 obtained for several chronic diseases as a group. No other studies have analysed changes 80 in smoking habits and smoking-related mortality in Mexican individuals with diabetes.

81 Added value of this study

To our knowledge, this is the first analysis of longitudinal data of Mexican adults with diabetes (n=24,200) followed over 17 years, to examine the association between smoking and all-cause and cause-specific mortality. Compared with never smokers with diabetes, former and daily smokers with diabetes had elevated mortality. Among daily smokers there was higher risk of death due to cardiovascular disease, acute diabetes complications, lung

It is made available under a CC-BY-NC-ND 4.0 International license .

87 cancer and COPD. Our results are generally consistent with previous analyses that have

88 found smoking as a significant risk factor for higher mortality in individuals with diabetes.

89 Our estimates, however, are comparably lower for all-cause mortality, possibly related to

- 90 distinct smoking habits specific to the Mexican population with diabetes.
- 91 Implications of all available evidence

92 Our results confirm that smoking is a significant risk factor for all-cause and cause-specific 93 mortality among Mexican adults with diabetes. Strategies to promote smoking cessation 94 among individuals with diabetes should be encouraged, particularly given that tobacco use 95 is a modifiable risk factor. This is especially meaningful in middle- to lower-income 96 countries like Mexico, where diabetes prevalence is increasing and achieving glycaemic 97 targets remains a challenge.

It is made available under a CC-BY-NC-ND 4.0 International license .

99 INTRODUCTION

100 Diabetes mellitus is a significant public health problem, with over 530 million individuals 101 living with the disease and around 6.7 million deaths attributable to diabetes worldwide in 2021¹. In Mexico, diabetes prevalence has tripled in the last three decades^{2,3} and currently 102 affects one in six Mexican adults¹. Besides the microvascular complications associated 103 104 with this condition, diabetes is a well-documented accelerant of cardiovascular disease 105 (CVD), which is the leading cause of premature mortality in Mexico. While comprehensive 106 risk factor management to reduce CVD risk in people with diabetes is an integral aspect of diabetes care⁴, addressing modifiable risk factors to reduce CVD burden remains a 107 challenge in Mexico². A key pervasive modifiable risk factor for diabetes and CVD 108 109 incidence and mortality is tobacco smoking. Despite ratification of the WHO's Framework 110 on Tobacco Control (FCTC) in 2014, prevalence of current smoking among Mexican adults 111 has remained relatively stable in the past decade, with nearly 1 in every 5 Mexican adults reporting current smoking in 2016⁵. While broader implementation of the FCTC is needed, 112 113 characterizing mortality risk attributed to smoking in Mexican adults with diabetes could 114 help inform tailored strategies for smoking cessation in this population.

115 The Mexico City Prospective Study (MCPS) is a large blood-based prospective study of 116 150.000 adults who were recruited between 1998 and 2004 and have been tracked for 117 cause-specific mortality ever since. A previous analysis of the MCPS identified an 118 increased risk of all-cause mortality among disease-free former and current smokers. Risk 119 of all-cause mortality was increased even among adults who reported low-intensity daily 120 smoking. However, participants with diabetes and other chronic diseases were excluded to 121 minimize reverse causality⁶. Despite the important contribution of this analysis to the 122 literature on smoking and mortality, smoking patterns in people with diabetes as well as 123 smoking-related mortality in Mexican adults with diabetes remains unexplored. In this 124 study, we aim to characterize patterns of tobacco use in individuals with diabetes and to

It is made available under a CC-BY-NC-ND 4.0 International license .

estimate the effect of smoking on all-cause and cause-specific mortality, exploring the influence of diabetes-related factors (glycaemic control and disease duration) as potential modifiers of this association.

128 **METHODS**

129 <u>Cohort characteristics</u>

We analysed data from participants enrolled in the MCPS, a prospective, population-based 130 131 cohort study with a baseline survey conducted from 1998 to 2004⁷. Households from two 132 urban districts of Mexico City (Coyoacán and Iztapalapa) were visited, and every adult ≥35 133 years was invited to participate. In total, 159,755 individuals were recruited, and 134 information was collected regarding age, sex, lifestyle habits, self-reported medical history, 135 use of medications, and socio-demographic information including education, civil status, 136 occupation, and monthly income. Clinical measurements (weight, height, and blood 137 pressure) were obtained, and a non-fasting 10-mL blood sample was collected for 138 subsequent analysis. From 2015-2019, a follow-up survey was conducted on 10,143 139 surviving participants, obtaining similar data regarding lifestyle habits, medical history, 140 clinical measurements, and another blood sample as described previously⁸. Blood 141 samples, both at baseline and resurvey examinations, were stored overnight in a central 142 laboratory, separated into plasma and buffy coat, and then frozen to -80°C. Afterwards, 143 samples were shipped to the University of Oxford for analysis and storage. Assays of 144 HbA1c were performed from buffy coat samples in the Clinical Trial Service Unit and 145 Epidemiological Studies Unit's Wolfson laboratory, which has International Organization for Standardization (ISO)-17025 accreditation, as described previously⁹. The study protocol 146 147 was approved by the corresponding ethics committees at the Mexican Ministry of Health. 148 the Mexican National Council for Science and Technology, and the University of Oxford. All 149 study participants provided written informed consent.

It is made available under a CC-BY-NC-ND 4.0 International license .

151 <u>Study population</u>

152 We defined diabetes mellitus according to self-reported medical diagnosis of diabetes, 153 use of diabetes medication (biguanides, sulfonylureas, insulin or other), or HbA1c $\geq 6.5\%^{10}$. 154 Diagnosed diabetes was defined as previous medical diagnosis of diabetes or use of 155 glucose lowering medication and undiagnosed diabetes as HbA1c ≥6.5% in an individual 156 without a previous diagnosis of diabetes. Given the heterogeneity of diabetes mellitus¹¹, 157 and to better account for diabetes-related variables, the primary analysis was restricted to 158 individuals with previously diagnosed or undiagnosed diabetes mellitus, excluding 159 participants without diabetes. To address the possibility of reverse causality in the 160 association between smoking and all-cause mortality, we excluded participants who 161 reported comorbidities other than diabetes at baseline, including ischaemic heart disease, 162 pulmonary disease, chronic kidney disease, cirrhosis, or cancer. We also excluded 163 individuals with missing covariates or with uncertain mortality linkage.

164 <u>Smoking related variables</u>

165 We defined smoking status according to baseline interview information. Never smokers 166 were classified as those who reported never smoking, former smokers as those who reported having smoked previously but not currently and current smokers as those having 167 168 ever smoked and smoking currently (daily or non-daily). We classified smoking intensity 169 into five categories (never smoker, ex-smoker, current non-daily smoker, current daily 170 smoker <10 cigarettes per day, and current daily smoker \geq 10 cigarettes per day), and age 171 when started smoking into three categories (<15 years, 15-23 years, \geq 24 years). In former 172 smokers, no data was available regarding time since they stopped smoking; therefore, we 173 were unable to explore this characteristic. We also analysed changes in smoking status 174 between baseline interview and resurvey to explore changes in smoking behaviour over 175 the study period. To do this, we matched surviving individuals who were included in the 176 main mortality analysis at baseline and resurveyed during the 2015-2019 period. Then, we

It is made available under a CC-BY-NC-ND 4.0 International license .

177 calculated the proportion of participants with a given smoking status at baseline and the

178 proportion at resurvey.

179 Mortality follow-up

180 Mortality follow-up of participants was done through electronic probabilistic linkage to death registries, with deaths tracked up to December 31st, 2020, and registered according 181 to the International Classification of Diseases 10th Revision (ICD-10). Cause-specific 182 183 mortality was classified into several categories (cardiovascular, myocardial infarction, 184 stroke, other vascular, acute diabetes complications [diabetic coma and ketoacidosis], lung 185 cancer, non-lung cancer, COPD, other respiratory, renal, hepatobiliary, and gastric) in 186 accordance with the underlying causes of death determined by study clinicians. The 187 specific ICD-10 codes used for every cause and the number of deaths in each of them are 188 provided in Supplementary Table 1.

189 Statistical analyses

190 For descriptive analyses, we calculated mean and standard deviation in continuous 191 variables (median and interguartile range for HbA1c, number of cigarettes per day and age 192 started smoking), and proportions for categorical variables. To explore the association 193 between smoking, all-cause and cause-specific mortality amongst individuals with 194 diabetes, we fitted Cox proportional hazard regression models to estimate adjusted hazard 195 ratios (HR) for former and current smokers using individuals with diabetes who were never 196 smokers as the reference group with analyses restricted to premature mortality (deaths at 197 ages 35-74 years). All models were stratified by sex and age at risk (5-year age groups)¹² 198 and adjusted for place of residence (Coyoacán or Iztapalapa), educational level 199 (elementary, high school, university, other), body mass index (BMI), HbA1c, time since 200 diabetes diagnosis, and alcohol consumption. We tested the proportional hazards 201 assumption using Schoenfeld residuals. As sensitivity analyses, we fitted separate Cox 202 models for males and females to further characterize whether there are different risk

It is made available under a CC-BY-NC-ND 4.0 International license .

profiles by sex. We estimated attributable fraction with the formula (RR - 1) / RR. In the text, conventional 95% confidence intervals (CI) comparing two groups are used. In the figures, however, group specific 95% CIs, are shown for every RR (including the reference group); these were estimated using floating absolute risks to reflect the amount of information in each category¹³. All statistical analyses were conducted using R software version 4.2.1.

209 **RESULTS**

210 <u>Smoking status and baseline characteristics of participants with diabetes</u>

211 Among 159,755 participants recruited from 1998 to 2004, we identified 29,948 individuals 212 with diabetes at baseline. Of these, 3,953 were excluded because they had comorbidities 213 other than diabetes (ischemic heart disease, pulmonary disease, chronic kidney disease, 214 cirrhosis, or cancer) and another 1,795 were excluded due to missing covariate or 215 mortality data. In total, we included 24,200 participants with diabetes with complete data 216 on the mortality analyses (Supplementary Figure 1). Among women, 10,724 (67.1%) 217 reported being never smokers, 2,498 (15.6%) former smokers, and 2,753 (17.2%) current 218 smokers at baseline, of whom 1,667 (60.6%) were daily smokers and 1,086 (39.4%) non-219 daily smokers (Table 1). Compared to female never smokers, female daily smokers were 220 younger, had worse glycaemic control (especially those smoking <10 cig/d) and a slightly 221 higher body mass index (BMI). Among men, there was a lower proportion of never 222 smokers with 1,554 (18.89%), and higher proportions of former and current smokers, with 223 2,875 (34.95%) and 3,796 (46.2%), respectively. Among current smokers, 2,629 men 224 (69.3%) were daily smokers and 1,167 (30.7%) were non-daily smokers. Compared to 225 male never smokers, male daily smokers were younger, had worse glycaemic control, and 226 the median age at which they started smoking was 17 years (IQR 15, 20). In women, the 227 greatest proportion of participants were never smokers and the proportion of current 228 smokers decreased with age. Cessation, however, was less common in this group with a

It is made available under a CC-BY-NC-ND 4.0 International license .

229 consistent number of former smokers across all age cohorts (**Figure 1**). In men, on the 230 other hand, there was a higher proportion of current smokers and the proportion of former 231 smokers increased with age. The proportion of never smokers was relatively low 232 regardless of age. Amongst current smokers, the prevalence of non-daily smoking was 233 higher at younger ages for both men and women, low-intensity daily smoking (<10 cig/day) 234 increased for older individuals irrespective of sex, and high-intensity smoking remained 235 stable throughout all age groups (**Supplementary Figure 2**).

236 Smoking status of participants with diabetes at resurvey

237 Smoking status changed significantly during follow-up. Among 10,143 participants 238 resurveyed, we identified 1,246 individuals initially classified with diabetes (diagnosed and 239 undiagnosed) whose data was used in the main mortality analyses. Of these surviving 240 participants, 666 (53.5%) were never smokers, 239 (19.2%) were former smokers and 341 241 (27.4%) were current smokers at baseline. Among never smokers, most remained as such 242 and <1% started smoking during follow-up. Similarly, among former smokers, 71.5% 243 remained as former smokers and only 3.7% restarted smoking (with the remaining 24.7% 244 reporting never smoking at resurvey). However, changes in smoking status were most 245 noticeable in current smokers. Over 59% reported quitting during the follow-up period, and 246 only 28.4% continued smoking at resurvey. The median number of cigarettes smoked per 247 day at resurvey among current smokers and former smokers was similar. At resurvey, 248 those who were former smokers had better glycaemic control than current smokers (Table

249 **2, Supplementary Figure 3**).

250 <u>All-cause mortality and smoking status among individuals with diabetes</u>

Among 24,200 participants with diabetes and after a median follow-up of 17.65 years, there were a total of 5,087 deaths at ages 35 to 74 years, 2,893 in women and 2,194 in men. Compared to never smokers, there was an increased risk for all-cause mortality among former (HR 1.08, 95%CI 1.01–1.17) and current smokers (HR 1.11, 95%CI 1.03–

It is made available under a CC-BY-NC-ND 4.0 International license .

255 1.20, Figure 2A), with similar relative risks in daily and non-daily smokers (Figure 2B). 256 Among daily smokers, there was increased risk in individuals who smoked ≥10 257 cigarettes/day (HR 1.28, 95%CI 1.14–1.43, Figure 2C). There was similar mortality risk 258 across age categories, being highest among those who started smoking <15 years (HR 259 1.19, 95%CI 1.03–1.37, Figure 2D). Exploring all-cause mortality risk in former smokers, 260 we found increased risk for participants who previously smoked ≥10 cigarettes/day (HR 261 1.16, 95%CI 1.02–1.31) but similar RRs irrespective of age starting (Figure 2E, F). 262 Estimating attributable fraction, our results indicate that 7% of deaths in former smokers 263 and around 22% in ≥10 cigarettes/day smokers aged 35-74 years could be prevented by 264 avoiding smoking exposure in persons with diabetes.

265 Smoking and cause-specific mortality among individuals with diabetes

266 Compared to never smokers, daily smokers had a significantly higher risk of 267 cardiovascular mortality especially in those smoking ≥ 10 cigarettes/day (Figure 3). There 268 was an increased risk of myocardial infarction related mortality in participants who smoked 269 ≥10 cigarettes/day, higher risk of other vascular deaths in those who smoked ≥10 270 cigarettes/day, and a significantly higher risk for acute diabetes complications in 271 participants who smoked ≥10 cigarettes/day. As expected, there were higher risks of death 272 due to lung cancer and COPD especially in those who smoked <10 and ≥10 cigarettes per 273 day, respectively. There was no association between smoking and mortality due to renal 274 causes, stroke, hepatobiliary or gastrointestinal deaths, nor non-lung cancer, although the 275 power to detect an association was probably low in the latter four categories. Finally, 276 among former smokers, there was an increased risk of death due to acute diabetes complications, COPD, and hepatobiliary (Supplementary Figure 4). 277

278 Sensitivity analysis

279 Separate models for men and women were fitted to determine whether there are different 280 risks by sex, results which are shown in **Supplementary Figure 5.** There were a total of

It is made available under a CC-BY-NC-ND 4.0 International license .

3,528 deaths at ages ≥75 years, 2,198 in women and 1,330 in men. The estimated RR are
shown in Supplementary Figure 6.

283 **DISCUSSION**

284 In this study of 24,200 participants with diabetes and no other comorbidities in the Mexico 285 City Prospective Study, daily and non-daily smoking were associated with an increased 286 risk for all-cause mortality in a dose-dependent manner. Daily smokers had higher 287 mortality risk in those who smoked ≥10 cigarettes/day and in participants who started 288 smoking aged <15 years. Notably, over 50% of current smokers at baseline had stopped 289 smoking at resurvey, which suggests a significant change in smoking habits during follow-290 up. Daily smokers were also at increased risk of death due to causes directly related to 291 smoking (cardiovascular disease, myocardial infarction, other vascular disease, lung 292 cancer and COPD), but also due to acute diabetes complications. Among former smokers 293 with diabetes, a significant proportion remained as such at resurvey, with increased 294 mortality risk in those who previously smoked ≥10 cigarettes/day and in those who started 295 smoking at ages 15-24. Former smokers were at increased risk of death primarily due to 296 COPD, hepatobiliary disease and, interestingly, acute diabetes complications as well. 297 These findings confirm that smoking represents an excess risk that is modifiable in this 298 population and support the notion that it remains a significant risk factor to be considered 299 to reduce cardiovascular risk as part of long-term diabetes management.

The effect of smoking on all-cause and cause-specific mortality has been extensively reported in the general population^{14,15} and numerous studies have also explored the association between smoking and mortality risk in individuals with diabetes, finding a predominately positive association^{16–18}. Regarding cause-specific mortality, smoking among individuals with diabetes has been associated with significantly increased risk for coronary heart disease, stroke, and peripheral arterial disease^{19,20}. Our findings in this subgroup of participants are in line to those reported previously for all-cause mortality,

It is made available under a CC-BY-NC-ND 4.0 International license .

albeit with lower estimates for both former and daily smokers¹⁹; and our cause-specific 307 mortality analysis identified similar risk associations, primarily with cardiovascular disease 308 309 and myocardial infarction for heavy smokers, but not with stroke probably related to lack of 310 statistical power in our study population. Interestingly, our results show a significant impact 311 on death related to acute hyperglycaemic crises in former and daily smokers. Smoking is 312 not considered a typical risk factor for the development of either diabetic ketoacidosis or 313 hyperglycaemic hyperosmolar state; however concomitant illness such as myocardial 314 infarction or cerebrovascular events can be precipitating causes (among others like poor adherence to treatment or infection)^{21,22}. Consequently, the observed association in our 315 316 analysis might be due to poor baseline glycaemic control and the known association 317 between smoking and cardiovascular events, which might lead to higher risk of developing 318 a precipitating cause and increased risk of acute glycaemic crises mortality in daily and 319 former smokers. These findings should further strengthen the fact that smoking cessation 320 represents a pivotal intervention to reduce mortality risk for individuals with diabetes.

321 In Mexico, a previous analysis of the MCPS on healthy individuals found that smoking was 322 responsible for significantly higher mortality risk among active smokers with a doseresponse relationship⁶, representing the first prospective analysis of smoking-related 323 324 mortality in Mexican population. Although smoking prevalence in Mexico declined 325 significantly from 2000 to 2010, there has been a slight increase in prevalence between 326 2011 and 2016. Moreover, prevalence of previously diagnosed diabetes has increased 327 dramatically in Mexico reaching 10.2% in 2021³. Even though smoking cessation is 328 advised for every person with diabetes, it has been suggested that individuals with chronic diseases, particularly younger persons, have higher prevalence of smoking^{23,24}. Notably, 329 330 the smoking trends among individuals with diabetes in Mexico are largely unknown, and so 331 is the mortality risk associated with smoking, thus the rational to explore tobacco use in 332 this subgroup of participants. It should be noted as well that previous analyses of MCPS

333 have found high mortality rates in individuals with diabetes, which accounts for at least a third of all deaths at ages 35-74 years²⁵. Given this conditions, even if the smoking-related 334 335 RRs found in this analysis are somewhat lower than previously reported in individuals with diabetes¹⁹ and in disease-free participants⁶, the smoking-related mortality risk for 336 337 individuals with diabetes might be similar or even greater in this population. Finally, it 338 should be highlighted that several interventions have proved effective to promote smoking cessation in individuals with diabetes^{4,26}, which emphasizes the importance of improving 339 340 public health policies directed towards smoking cessation.

341 Strengths and limitations

342 Our study has several strengths, including its prospective design, which allows to establish 343 a potentially causal association between mortality risk and smoking in individuals with 344 diabetes, the large sample size obtained from two urban districts in Mexico City and the 345 analysis of resurvey data to assess changes of smoking habits during follow-up. We 346 recognize however some limitations which should be considered to adequately interpret 347 our findings. First, information regarding characterization of former smokers is incomplete, 348 which did not allow us to estimate the effect of time since smoking cessation in all-cause 349 mortality. Second, because resurvey information was collected only in a subset of surviving 350 participants, we were unable to explore changes in smoking exposure during follow-up for 351 every individual and, consequently, our estimates using baseline interview information do 352 not account for changes in smoking patterns over time, which might lead to a potential 353 underestimation of RRs. Reverse causality might also be a concern. Diabetes diagnosis 354 might change the smoking status of participants which might be of concern in former 355 smokers and in participants with undiagnosed diabetes. Given that we have limited 356 information regarding why and when former smokers guitted and the precise moment 357 undiagnosed participants were diagnosed with diabetes, caution should be taken 358 regarding our estimates in these categories. Finally, due to the observational nature of the

It is made available under a CC-BY-NC-ND 4.0 International license .

study, we are unable to rule out residual confounding despite controlling for knownmodifiers of mortality risk in statistical analyses.

361 *Conclusions and perspectives*

362 In summary, our results highlight that smoking in individuals with diabetes still represents 363 an important risk factor for all-cause and cause-specific mortality. Former smokers with 364 diabetes are at increased risk dependent on previous smoking intensity, whilst daily 365 smokers have a dose-dependent increase in mortality risk, particularly for individuals who 366 started smoking at younger ages. Notably, smoking is associated with higher risk of acute 367 diabetes complications, which support the view that smoking cessation is still a relevant 368 target to improve diabetes management and that it should be strongly recommended 369 during patient counselling.

It is made available under a CC-BY-NC-ND 4.0 International license .

370 ACKNOWLEDGMENTS

371 This project was registered and approved by the Research Committee at Instituto Nacional 372 de Geriatría, project number DI-PI-006/2020. CAFM is enrolled at the PECEM Program of 373 the Faculty of Medicine at UNAM. DRG and CAFM are supported by CONACyT. The 374 authors thank the participants for their willingness to take part in this prospective study 20 375 years ago. This research was conducted using Mexico City Prospective Study (MCPS) 376 data obtained through an open-access data request (application number 2022-012). We 377 want to thank Jonathan Emberson and Diego Aguilar-Ramirez for their very thoughtful 378 comments and methodological support on this manuscript.

379 AUTHOR CONTRIBUTIONS

380 Establishing the cohort: JBC, PKM, JAD and RTC. Obtaining funding: JBC, PKM, JAD, 381 RTC and OYBC. Data acquisition, analysis, or interpretation of data: DRG, OYBC, CAFM, PSC, ANL, MRBA, LFC, AVV, JPE, JPDS, AKG, PAV, PKM, RTC, JAD, JAS, NEAV. 382 383 Drafting first version of manuscript: DRG, OYBC. Critical revision of the report for 384 important intellectual content: All authors. All authors have seen and approved the final 385 version and agreed to its publication. Each author contributed important intellectual 386 content during manuscript drafting or revision and accepts accountability for the overall 387 work by ensuring that questions pertaining to the accuracy or integrity of any portion of the 388 work are appropriately investigated and resolved.

389 **DATA AVAILABILITY:** Data from the Mexico City Prospective Study are available to bona 390 fide researchers. For more details, the study's Data and Sample Sharing policy may be 391 downloaded (in English or Spanish) from <u>https://www.ctsu.ox.ac.uk/research/mcps</u>. 392 Available study data can be examined in detail through the study's Data Showcase, 393 available at <u>https://datashare.ndph.ox.ac.uk/mexico/</u>. Code is available for reproducibility 394 of results at <u>https://github.com/oyaxbell/smoking diabetes mcps/</u>

395 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 396 **FUNDING:** This research was supported by Instituto Nacional de Geriatría in Mexico. The
- 397 funding sources had no role in the design, conduct or analysis of the study or the decision
- 398 to submit the manuscript for publication.

It is made available under a CC-BY-NC-ND 4.0 International license .

399 **REFERENCES**

400 1. International Diabetes Federation. *IDF Diabetes Atlas.* 10th ed. International401 Diabetes Federation; 2021.

402 2. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas C, Hernández-Avila M.
403 Epidemiology of diabetes mellitus in Mexico. *Nutr Rev.* 2017;75(suppl 1).
404 doi:10.1093/nutrit/nuw030

3. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutierrez T. *Encuesta Nacional de Salud y Nutrición 2021 Sobre Covid-19. Resultados Nacionales.* Instituto Nacional de
Salud Pública; 2022.

408 4. ElSayed NA, Aleppo G, Aroda VR, et al. 5. Facilitating Positive Health Behaviors
409 and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023.
410 *Diabetes Care*. 2023;46(Supplement_1):S68-S96. doi:10.2337/dc23-S005

5. Zavala-Arciniega L, Reynales-Shigematsu LM, Levy DT, et al. Smoking trends in
Mexico, 2002–2016: before and after the ratification of the WHO's Framework Convention
on Tobacco Control. *Tob Control.* 2020;29(6):687-691. doi:10.1136/tobaccocontrol-2019055153

415 6. Thomson B, Tapia-Conyer R, Lacey B, et al. Low-intensity daily smoking and
416 cause-specific mortality in Mexico: prospective study of 150 000 adults. *Int J Epidemiol.*417 2021;50(3):955-964. doi:10.1093/ije/dyab013

Tapia-Conyer R, Kuri-Morales P, Alegre-Díaz J, et al. Cohort Profile: The Mexico
City Prospective Study. *Int J Epidemiol*. 2006;35(2):243-249. doi:10.1093/ije/dyl042

Aguilar-Ramirez D, Alegre-Díaz J, Gnatiuc L, et al. Changes in the Diagnosis and
Management of Diabetes in Mexico City Between 1998–2004 and 2015–2019. *Diabetes Care*. 2021;44(4):944-951. doi:10.2337/dc20-2276

423 9. Herrington WG, Alegre-Díaz J, Wade R, et al. Effect of diabetes duration and
424 glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based
425 prospective cohort study. *Lancet Diabetes Endocrinol.* 2018;6(6):455-463.
426 doi:10.1016/S2213-8587(18)30050-0

427 10. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of
428 Diabetes: Standards of Care in Diabetes—2023. *Diabetes Care*.
429 2023;46(Supplement_1):S19-S40. doi:10.2337/dc23-S002

430 11. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes
431 and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet*432 *Diabetes Endocrinol.* 2018;6(5):361-369. doi:10.1016/S2213-8587(18)30051-2

It is made available under a CC-BY-NC-ND 4.0 International license .

433 12. Carstensen B. *Epidemiology with R*. Oxford University Press; 2021.

434 13. Plummer M. Improved estimates of floating absolute risk. Stat Med. 2004;23(1):93-

435 104. doi:10.1002/sim.1485

436 14. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years'
437 observations on male British doctors. *BMJ*. 2004;328(7455):1519.
438 doi:10.1136/bmj.38142.554479.AE

439 15. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century Hazards of
440 Smoking and Benefits of Cessation in the United States. *N Engl J Med*. 2013;368(4):341441 350. doi:10.1056/NEJMsa1211128

442 16. Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and Mortality
443 Among Women With Type 2 Diabetes. *Diabetes Care*. 2001;24(12):2043-2048.
444 doi:10.2337/diacare.24.12.2043

Vazquez-Benitez G, Desai JR, Xu S, et al. Preventable Major Cardiovascular
Events Associated With Uncontrolled Glucose, Blood Pressure, and Lipids and Active
Smoking in Adults With Diabetes With and Without Cardiovascular Disease: A
Contemporary Analysis. *Diabetes Care*. 2015;38(5):905-912. doi:10.2337/dc14-1877

18. Rawshani A, Rawshani A, Franzén S, et al. Risk Factors, Mortality, and
Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.*2018;379(7):633-644. doi:10.1056/NEJMoa1800256

452 19. Pan A, Wang Y, Talaei M, Hu FB. Relation of Smoking With Total Mortality and
453 Cardiovascular Events Among Patients With Diabetes Mellitus: A Meta-Analysis and
454 Systematic Review. *Circulation*. 2015;132(19):1795-1804.
455 doi:10.1161/CIRCULATIONAHA.115.017926

Qin R, Chen T, Lou Q, Yu D. Excess risk of mortality and cardiovascular events
associated with smoking among patients with diabetes: Meta-analysis of observational
prospective studies. *Int J Cardiol.* 2013;167(2):342-350. doi:10.1016/j.ijcard.2011.12.100

459 21. Umpierrez G, Korytkowski M. Diabetic emergencies — Ketoacidosis,
460 hyperglycaemic hyperosmolar state and hypoglycaemia. *Nat Rev Endocrinol.*461 2016;12(4):222-232. doi:10.1038/nrendo.2016.15

462 22. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. *Nat Rev*463 *Dis Primer*. 2020;6(1):40. doi:10.1038/s41572-020-0165-1

464 23. Bae J. Differences in Cigarette Use Behaviors by Age at the Time of Diagnosis
465 With Diabetes From Young Adulthood to Adulthood: Results From the National
466 Longitudinal Study of Adolescent Health. *J Prev Med Pub Health*. 2013;46(5):249-260.

It is made available under a CC-BY-NC-ND 4.0 International license .

467 doi:10.3961/jpmph.2013.46.5.249

468 24. Stanton CA, Keith DR, Gaalema DE, et al. Trends in tobacco use among US adults
469 with chronic health conditions: National Survey on Drug Use and Health 2005–2013. *Prev*470 *Med.* 2016;92:160-168. doi:10.1016/j.ypmed.2016.04.008

471 25. Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and Cause472 Specific Mortality in Mexico City. *N Engl J Med.* 2016;375(20):1961-1971.
473 doi:10.1056/NEJMoa1605368

474 26. Tonstad S, Lawrence D. Varenicline in smokers with diabetes: A pooled analysis of
475 15 randomized, placebo-controlled studies of varenicline. *J Diabetes Investig.*476 2017;8(1):93-100. doi:10.1111/jdi.12543

3.02 (±11.19)	52.65 (±10.35)	58.62 (±12.3)	61.45 (±11.67)	52.98 (±10.94)	55.38 (±11.21)	54.62 (±10.45)
30 (33.23%)	123 (32.98%)	514 (33.08%)	1026 (35.69%)	389 (33.33%)	629 (38.17%)	383 (39.04%)
94 (7.26%)	35 (9.38%)	254 (16.34%)	410 (14.26%)	193 (16.54%)	217 (13.17%)	184 (18.76%)
85 (22.02%)	87 (23.32%)	323 (20.79%)	528 (18.37%)	272 (23.31%)	397 (24.09%)	225 (22.94%)
16 (55.33%)	211 (56.57%)	774 (49.81%)	1521 (52.9%)	608 (52.1%)	858 (52.06%)	460 (46.89%)
99 (15.38%)	40 (10.72%)	203 (13.06%)	416 (14.47%)	94 (8.05%)	176 (10.68%)	112 (11.42%)
20 (16, 29)	18 (15, 24)	_	16 (14, 20)	18 (15, 20)	17 (15, 20)	16 (14, 19)
3 (2, 5)	15 (10, 20)	_	5 (2, 20)	2 (1, 3)	4 (2, 6)	15 (10, 20)
74 (7, 10.84)	8.37 (6.82, 10.93)	8.46 (6.82, 10.48)	8.1 (6.73, 10.29)	8.83 (7, 10.75)	8.65 (6.91, 10.75)	9.01 (7, 10.84)
23 (24.96%)	112 (30.03%)	442 (28.44%)	914 (31.79%)	287 (24.59%)	435 (26.4%)	236 (24.06%)
10 (39.41%)	135 (36.19%)	626 (40.28%)	1157 (40.24%)	461 (39.5%)	639 (38.77%)	386 (39.35%)
61 (35.63%)	126 (33.78%)	486 (31.27%)	804 (27.97%)	419 (35.9%)	574 (34.83%)	359 (36.6%)
).34 (±14.79)	72.53 (±14.97)	75.22 (±13.41)	75.38 (±13.22)	76.52 (±13.95)	74.98 (±13.21)	76.17 (±14.24)
51.85 (±6.16)	153.19 (±6.59)	162.84 (±6.85)	163.07 (±6.93)	163.44 (±7)	163.54 (±6.81)	165.42 (±7.26)
0.46 (±5.89)	30.9 (±6.17)	28.34 (±4.58)	28.32 (±4.57)	28.61 (±4.9)	28 (±4.51)	27.84 (±5.28)
1.42 (±18.33)	131.27 (±17.43)	133.75 (±17.74)	134.85 (±18.38)	131.63 (±17.33)	132.2 (±17.43)	131.46 (±17.6)
3.73 (±10.47)	83.56 (±11.16)	86.12 (±11.08)	86.11 (±11.17)	85.48 (±10.89)	85.41 (±11.15)	84.99 (±11.01)
81 (13.99%)	44 (11.8%)	195 (12.55%)	373 (12.97%)	130 (11.14%)	176 (10.68%)	114 (11.62%)
05 (46.75%)	169 (45.31%)	729 (46.91%)	1501 (52.21%)	541 (46.36%)	788 (47.82%)	453 (46.18%)
80 (6.18%)	21 (5.63%)	74 (4.76%)	115 (4%)	44 (3.77%)	63 (3.82%)	34 (3.47%)

Body mass index.

It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .

	Smoking status at baseline			Other characteristics	
Smoking status at resurvey	Never smoker (n = 666)	Former smoker (n = 239)	Current smoker (n = 341)	HbA1c level at resurvey (%)	No. of cigarettes/d at resurvey
Never smoker	622 (93.39%)	59 (24.69%)	40 (11.73%)	7.73 (6.36, 9.38)	-
Former smoker	41 (6.16%)	171 (71.55%)	204 (59.82%)	7.64 (6.45, 9.56)	3 (2, 8)
Current smoker	3 (0.45%)	9 (3.77%)	97 (28.45%)	8.19 (6.43, 9.61)	3 (2, 10)

480

481 **Table 2.** Changes in reported smoking habits from baseline to resurvey. HbA1c: Glycated

482 haemoglobin.

It is made available under a CC-BY-NC-ND 4.0 International license .

483 FIGURES



Figure 1. Smoking prevalence by age and sex. (A) Smoking status by age in women, (B)
Smoking status by age in men.

It is made available under a CC-BY-NC-ND 4.0 International license .



498 **Figure 2.** Hazard ratios for all-cause mortality by smoking status in individuals with 499 diabetes. (A) Smoking status and all-cause mortality, (B) Non-daily, daily smoking and all-

It is made available under a CC-BY-NC-ND 4.0 International license .

500	cause mortality in current smokers, (C) Number of cigarettes/day and all-cause mortality in
501	daily smokers, (D) Age started smoking and all-cause mortality in daily smokers, (E)
502	Number of cigarettes/day and all-cause mortality in former smokers, (F) Age started
503	smoking and all-cause mortality in former smokers. All models were stratified by sex and
504	age at risk (5-year age groups) and adjusted for place of residence (Coyoacán or
505	Iztapalapa), educational level (elementary, high school, university, other), body mass index
506	(BMI), HbA1c, time since diabetes diagnosis, and alcohol consumption.

It is made available under a CC-BY-NC-ND 4.0 International license .

507

Cause of death	No. of cigs/d	No. of deaths		HR (95% CI)
Cardiovascular	Never	629		1 (0.9-1.11)
	<10 cig/d	202	-	1.11 (0.97-1.27)
	≥10 cig/d	133		1.48 (1.24-1.76)
Myocardial infarction	Never	451		1 (0.89-1.13)
	<10 cig/d	147		1.09 (0.93-1.29)
	≥10 cig/d	95		1.43 (1.16-1.75)
Stroke	Never	131	— —	1 (0.8-1.25)
	<10 cig/d	38	_	1.14 (0.83-1.57)
	≥10 cig/d	18		1.13 (0.7-1.8)
Other vascular	Never	47		1 (0.69-1.45)
	<10 cig/d	17		1.18 (0.73-1.91)
	≥10 cig/d	20		2.69 (1.7-4.26)
Acute diabetes	Never	153		1 (0.82-1.22)
	<10 cig/d	56	_	1.33 (1.02-1.74)
	≥10 cig/d	45	_	2.29 (1.7-3.1)
Lung cancer	Never	15		1 (0.5-1.98)
	<10 cig/d	9		2.05 (1.07-3.95)
	≥10 cig/d	5		2.33 (0.95-5.7)
Non-lung cancer	Never	187		1 (0.83-1.2)
	<10 cig/d	51	— — —	1.12 (0.85-1.47)
	≥10 cig/d	21		1.01 (0.65-1.55)
COPD	Never	28		1 (0.62-1.61)
	<10 cig/d	6	•	1.17 (0.53-2.62)
	≥10 cig/d	15		5.86 (3.4-10.12)
Other respiratory	Never	217		1 (0.84-1.19)
	<10 cig/d	73		1.05 (0.83-1.32)
	≥10 cig/d	47	_	1.42 (1.06-1.9)
Renal	Never	689		1 (0.91-1.1)
	<10 cig/d	199		0.91 (0.79-1.05)
	≥10 cig/d	93		0.87 (0.7-1.07)
Hepatobiliary	Never	99		1 (0.78-1.28)
	<10 cig/d	34	_	1.01 (0.72-1.41)
	≥10 cig/d	19		1.11 (0.7-1.75)
Gastric	Never	92		1 (0.77-1.31)
	<10 cig/d	32		1.27 (0.9-1.8)
	≥10 cig/d	16		1.34 (0.81-2.22)
			0.50 1.0 2.0 4.0 8.0	

508

Figure 3. Cause-specific mortality in individuals with diabetes according to number of cigarettes smoked per day amongst daily smokers. COPD: Chronic obstructive pulmonary disease. All models were stratified by sex and age at risk (5-year age groups) and adjusted

It is made available under a CC-BY-NC-ND 4.0 International license .

- 512 for place of residence (Coyoacán or Iztapalapa), educational level (elementary, high
- 513 school, university, other), body mass index (BMI), HbA1c, time since diabetes diagnosis,
- and alcohol consumption.